Amir Belson, M.D.
Prior to conceiving of and starting ZipLine Medical, Amir Belson, M.D. founded NeoGuide Systems, a company that developed a platform technology for minimally invasive surgical procedures. NeoGuide was acquired by Intuitive Surgical in 2009. Dr. Belson founded Vascular Pathways, a company that developed an FDA cleared vascular intervention technology that has been chosen as one of the 10 best inventions of 2009 by Popular Science magazine. Vascular Pathways was acquired by C.R. Bard in 2015. Dr. Belson also founded Qool, which is developing innovative therapeutic hypothermia technology, Radiaction, which is developing radiation protection for healthcare providers, and Emboline, which is developing emolic protection technology for TAVI and other interventional cardiology procedures.
Dr. Belson graduated cum laude from the school of medicine of the Technion, Israel Institute of Technology, in Haifa, Israel. He completed his pediatric residency at Dana Children’s Hospital in Tel Aviv and his pediatric nephrology fellowship at Lucile Packard Children’s Hospital at Stanford University. He also served several years as a flight surgeon in the IDF air force rescue unit before moving to the US for a three year Pediatric Nephrology fellowship at Stanford University Medical Center. Dr. Belson also spent one year as a research fellow with the Biomedical Technology Innovation Program at Stanford.
Ted Driscoll, Ph.D.
Ted Driscoll is Managing Director at a new fund, DigitalDx Ventures, whose focus is on Diagnostics in a Big-Data and Personalized Medicine World. Previously he was a Partner at Decheng Capital, and a Partner at Claremont Creek Ventures leading Digital Healthcare. He led first investment in Natera (IPOed 2015), AssureX (acquired by Myriad Genetics for $410M) and GeneWeave (acquired by Roche for $425M). Prior to entering venture capital, he was an early leader/founder of five startups. His first startup, International Imaging Systems, built the first Digital Subtractive Angiography machines. He then led the team at Identix that pioneered the first digital fingerprint recognition, now used in the iPhone. Identix IPOed in 1984. He then joined Diasonics where he led the team that created the world’s first MRI scanners. He was then named Division President of a spinoff from Diasonics named Focus Surgery that pioneered noninvasive HIFU ablation surgery. This company IPOed in 1992. His last startup was Be Here Technologies, a 360degree imaging company, which was purchased by and incorporated into Google Streetview.
Kevin Cheng, Ph.D.
Kevin joined MVM in 2016. Prior to MVM, he worked across the life science and healthcare sector as a consultant at Bain & Company. Kevin completed his PhD in Oncology at the University of Cambridge, where he conducted translational research in the field of neural development.
Stephen Reeders, M.D.
Steve founded MVM in 1997. Prior to setting up MVM, he was responsible for early-stage healthcare investments at Saunders, Karp & Megrue in New York City. Between 1988 and 1993 Steve was an Investigator of the Howard Hughes Medical Institute at the Boyer Center for Molecular Medicine at Yale, where he was also an Associate Professor of Medicine and Genetics. He has published more than 50 papers on the molecular genetics of human disease.
Steve has been involved in starting several US biotechnology companies and was acting CEO at UpToDate In Medicine in Wellesley, Mass. He practised medicine at the John Radcliffe Hospital, Churchill Hospital, Guys Hospital, St Thomas’s Hospital, Hammersmith Hospital and the Institute of Neurology, Queen Square before taking up research into molecular genetics at Oxford University. He has a degree in Natural Sciences from Cambridge and a Doctorate in medicine from Oxford and is a member of the Royal College of Physicians of England.
Steve is a member of the boards of Ambio, Inc., Cheetah Medical, Inc., Pulmagen Therapeutics Ltd and Zipline Medical, Inc. He was previously a director of Beacon Endoscopic Ltd, BioVex Group, Inc., Cara Therapeutics, Inc., Clavis Pharma ASA, Domantis Ltd, Gendaq Ltd, Momenta Pharmaceuticals, Inc., New Chemical Entities, Inc., Nova Science Ltd, Sangamo Biosciences, Inc., UpToDate, Inc., Xention Ltd and Vascular Pathways, Inc.
John R. Tighe
John R. Tighe serves as Chief Executive Officer and president of ZipLine Medical, Inc. He also serves as a member of ZipLine’s board of directors. Prior to joining ZipLine, he was the CEO and president of PEAK Surgical, Inc. from 2006 to 2011. He was the first employee and also served as a Director of PEAK Surgical until their acquisition by Medtronic in 2011. Mr. Tighe has over 22 years of experience in the medical device industry and has worldwide commercialization experience in several medical specialties, including orthopaedics, ENT, and general surgery. Prior to PEAK Surgical he was senior vice president and general manager of all business units for ArthroCare Corporation, where he worked for 11 years. Before that, he served as national sales manager for Acufex Microsurgical, where he worked in various sales and management roles over a seven year period. Mr. Tighe holds a B.S. degree in Civil Engineering from the University of Maryland.
Dean Tozer has more than 25 years of experience in the global healthcare industry with an established track record of successfully launching and marketing innovative technologies. Mr. Tozer currently works as a consultant/advisor in the field of commercial and corporate strategy. His clients include HighCape portfolio companies as well as other commercial-stage start-up organizations.
Prior to his current role, he was President & CEO of Nuo Therapeutics, a biomedical company that markets innovative wound care products. He joined Nuo following his tenure as Vice President of Corporate Development for Shire Regenerative Medicine, where he led business development efforts for that division, including the 2012 acquisition of Pervasis Therapeutics. Tozer arrived at Shire through the 2011 acquisition of Advanced BioHealing, where he was Senior Vice President since the company’s inception in 2006. He is widely regarded as a key architect of the commercial strategy behind the re-launch and subsequent success of Dermagraft in the U.S. market.
Prior to working with early stage companies, he spent 10 years in the global pharmaceutical industry and lived in Toronto, Chicago and Tokyo while commercializing global blockbuster products such as Bextra & Celebrex.
From 2009 to 2013, Mr. Tozer also served as a founding executive and officer of The Alliance for Regenerative Medicine. He received a Bachelor of Commerce degree from Saint Mary’s University in Halifax, Nova Scotia and a Certified Management Accountant designation in Ontario, Canada.